Compositions and method for treatment and prophylaxis of inflammatory bowel disease
OwnerIra Milton TRACHTMANinventor
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD.
Claims18
An oral dosage form for the treatment or prophylaxis of inflammatory bowel disease due to bacterial infection, said dosage form comprising:
- (i) a delayed-release component comprising an amount of antibiotic effective to reduce colonization of pathogenic bacteria in the gastrointestinal tract, said antibiotic comprising a combination of sulfamethoxazole and trimethoprim;
- and
- (ii) an immediate-release component comprising a probiotic formulation in an amount effective to restore normal microflora colonies in the gut;
- wherein said immediate-release component releases said probiotic formulation upon contact with fluid in the stomach;
- and wherein said delayed-release component releases said antibiotic at a pH of 7 or greater.
A method for the treatment or prophylaxis of inflammatory bowel disease due to bacterial infection comprising administering to a patient in need thereof, an oral dosage form comprising:
- (i) a delayed-release component comprising an amount of antibiotic effective to reduce colonization of pathogenic bacteria in the gastrointestinal tract, said antibiotic comprising:
- from about 200 mg to about 800 mg of sulfamethoxazole;
- and
- from about 40 mg to about 160 mg of trimethoprim;
- and
- (ii) an immediate-release component comprising a probiotic formulation in an amount effective to restore normal microflora colonies in the gut;
- wherein said immediate-release component releases said probiotic formulation upon contact with fluid in the stomach;
- and wherein said delayed-release component releases said antibiotic at a pH of 7 or greater.
A method for the treatment or prophylaxis of inflammatory bowel disease due to bacterial infection comprising administering to a patient in need thereof, an oral dosage form comprising:
- (i) a delayed-release component comprising an amount of antibiotic effective to reduce colonization of pathogenic bacteria in the gastrointestinal tract, said antibiotic comprising:
- from about 200 mg to about 800 mg of sulfamethoxazole;
- and
- from about 40 mg to about 160 mg of trimethoprim;
- and
- (ii) an immediate-release component comprising a probiotic formulation in an amount effective to restore normal microflora colonies in the gut;
- wherein said immediate-release component releases said probiotic formulation upon contact with fluid in the stomach;
- and wherein said delayed-release component releases said antibiotic in the small intestine.
Dependencies are inferred from the claim text.